Trial report in Hypertension (Dallas, Tex. : 1979), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04434664 (BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) Trial
TypeinterventionalSponsorUniversity of PennsylvaniaRan2021 to 2024Enrolled50ConditionsHeart Failure With Preserved Ejection Fraction, HypertensionArmsAmlodipine Besylate, Metoprolol Succinate
3 · Its place in the literature
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Jordana B CohenRenal-Electrolyte and Hypertension Division (J.B.C., A.H., R.R.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.ORCID 0000-0003-4649-079X
Alavi HossainRenal-Electrolyte and Hypertension Division (J.B.C., A.H., R.R.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.ORCID 0009-0001-1899-7991
Jesse ChittamsDepartment of Biostatistics, Epidemiology, and Informatics (J.B.C., J.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Manyun ZhaoDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0009-0000-7673-7568
Jessica AfableDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0009-0005-1843-0281
Audrey GreenipDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0009-0007-2125-5036
Hannah MaynardDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).
Bianca PourmussaDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0000-0003-4763-795X
Stuart B PrennerDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0000-0002-6996-3804
Senthil SelvarajDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0000-0001-8418-7623
Raymond R TownsendRenal-Electrolyte and Hypertension Division (J.B.C., A.H., R.R.T.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.ORCID 0000-0002-3215-9118
Payman ZamaniDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0000-0002-9345-5834
Julio A ChirinosDivision of Cardiovascular Medicine, Hospital of the University of Pennsylvania and Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.H., J.C., M.Z., J.A., A.G., H.M., B.P., S.B.P., S.S., P.Z., J.A.C.).ORCID 0000-0001-9035-5670
Funding
NHLBI NIH HHS R01 HL153646
6 · The paper itself
Abstract
backgroundHypertension is present in 90% of individuals with heart failure with preserved ejection fraction (HFpEF) and is a major modifiable risk factor for the development of HFpEF. However, randomized controlled trial evidence for hypertension management in HFpEF is limited.
methodsIn a double-blind, randomized, crossover trial, we studied the effect of amlodipine 5 to 10 mg versus metoprolol succinate 100 to 200 mg (doses previously demonstrated to have comparable antihypertensive efficacy) for 4 weeks among adults with HFpEF and hypertension, without contraindications to initiating or withholding either drug. The primary outcome was the difference in mean home systolic blood pressure (BP) during the final week of each treatment.
resultsThe mean age of the 50 enrolled participants was 72±9 years, 34 (68%) were female, 33 (66%) were of Black race, mean blood pressure was 144±15/78±9 mm Hg, and 23 (46%) were receiving β-blockers before enrollment. Compared with metoprolol, systolic BP was 4 (95% CI, -7 to -1;
conclusionsOur findings support the use of dihydropyridine calcium channel blockers as a preferred alternative to β-blockers for the management of hypertension in HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04434664.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover Trial. · full record | Socratic